Close
  Indian J Med Microbiol
 

Figure 1: Experimental design. (A) During therapeutic treatment, PPX (0.1, 1, and 5 mg/kg, i.p., once a day) was administered from day 4 to day 14 after reserpine injection. Negative control group received vehicle solution (10 mL/kg, s.c.; 0.5% Tween 80 in PBS) at the same administration schemes. Baseline assessment of mechanical and thermal thresholds were evaluated before drug administration (day 0). On days 0, 3, 4, 5, 6, 9, 11, 13, and 14 post-reserpine-induction, animals were subjected to the following behavioral tests: i) open field test – days 4 and 14, ii) mechanical hypersensitivity – days 0, 3, 4, 9 and 14, iii) thermal stimulus – days 0, 3, 4, 9, and 14, iv) forced swim test – days 6 and 11, v) elevated plus-maze – days 5 and 13, and vi) splash test – days 5 and 13. Mice weight and observation searching for clinical signs of FM were evaluated daily over 15 days post-reserpine-administration. (B) Secondly, we assessed the preventive treatment with PPX (1 mg/kg, i.p.) during reserpine administration (days 1, 2, 3) 30 minutes after injection. On the 4th day, mice were treated with a respective drug, dosed 60 minutes before behavioral tests. Pregabalin (30 mg/kg, p.o.) used as positive control group, and the vehicle solution (0.5% Tween 80 in PBS, s.c., 10 mL/kg) was used as the negative control. We performed behavioral analysis—von Frey and tail-flick test (ST) after reserpine administration. On day 4 of the protocol, mice were euthanized to evaluate biochemical assays. FM: Fibromyalgia; PG: pregabalin; PPX: pramipexole.

Figure 1: Experimental design.
(A) During therapeutic treatment, PPX (0.1, 1, and 5 mg/kg, i.p., once a day) was administered from day 4 to day 14 after reserpine injection. Negative control group received vehicle solution (10 mL/kg, s.c.; 0.5% Tween 80 in PBS) at the same administration schemes. Baseline assessment of mechanical and thermal thresholds were evaluated before drug administration (day 0). On days 0, 3, 4, 5, 6, 9, 11, 13, and 14 post-reserpine-induction, animals were subjected to the following behavioral tests: i) open field test – days 4 and 14, ii) mechanical hypersensitivity – days 0, 3, 4, 9 and 14, iii) thermal stimulus – days 0, 3, 4, 9, and 14, iv) forced swim test – days 6 and 11, v) elevated plus-maze – days 5 and 13, and vi) splash test – days 5 and 13. Mice weight and observation searching for clinical signs of FM were evaluated daily over 15 days post-reserpine-administration. (B) Secondly, we assessed the preventive treatment with PPX (1 mg/kg, i.p.) during reserpine administration (days 1, 2, 3) 30 minutes after injection. On the 4<sup>th</sup> day, mice were treated with a respective drug, dosed 60 minutes before behavioral tests. Pregabalin (30 mg/kg, p.o.) used as positive control group, and the vehicle solution (0.5% Tween 80 in PBS, s.c., 10 mL/kg) was used as the negative control. We performed behavioral analysis—von Frey and tail-flick test (ST) after reserpine administration. On day 4 of the protocol, mice were euthanized to evaluate biochemical assays. FM: Fibromyalgia; PG: pregabalin; PPX: pramipexole.